<img alt="" src="https://secure.soil5hear.com/223550.png" style="display:none;">
Skip to content

 Hematological VitroScreen

The industry’s leading ex vivo platform for blood cancer research, delivering an extensive and unique repository of rare, clinically meaningful blood cancer models such as AML, ALL, CLL, MCL, and MM.

Enrolling until April 15th, 2025

 

 

Empower Your Blood Cancer Research with Our Vast Model Collection

Unlock new possibilities in blood cancer research with our unparalleled bank of never-passaged, hard-to-source bank of primary models of key hematological malignancies. Featuring primary models of ALL, AML, CLL, MCL, and MM, these clinically relevant models deliver patient-like responses, providing the reliability needed to advance your blood cancer drug discovery pipeline forward with certainty.

Clinically Relevant Models

Bank of primary patient blood cancer models that correlate with clinical outcomes

Industry's Largest Bank

Includes models representing major blood cancers including AML, ALL, CLL, MCL, & MM.

Multi-omic Characterization

Clinical annotations coupled with molecular datasets and clinical responses

Offers the largest, most thoroughly characterized model bank in the industry:

  • Primary models of Acute Myeloid Leukemia (AML)
  • Primary models of T-cell Acute Lymphoblastic Leukemia (T-ALL)
  • Primary models of B-cell Acute Lymphoblastic Leukemia (B-ALL) 
  • Primary models of Chronic Lymphocytic Leukemia (CLL)
  • Primary models of Mantle Cell Lymphoma (MCL)
  • Primary models of Multiple Myeloma (MM)

 

An ideal platform for ex vivo drug screening:

  • Model Characterization analysis is available with clinical metadata, NGS, Flow Cytometry, and Proteomics.
  • Carefully curated models with ex vivo and in vivo engraftment capabilities.
  • Co-culture modeling using AML Models with Autologous T Cells for Immuno-oncology therapeutic testing.
  • Multiple endpoint data options available, including Western blot, flow cytometry, and 4D proteomics.
  • 50% off on a Standard of Care agent arm (selected by Champions).
Copy of Heme VitroScreen Workflow + MDS & CMML

Figure 1: The Hematological VitroScreen Workflow

Endpoint options Hematologic screen May 2024

Figure 2: The range of assay endpoints available to customize your VitroScreen results

 

Exemplary Responses to Standard of Care (SoC)
Acute Myeloid Leukemia CTG-3950 - Standard of Care
AML Response to Ziftomenib
Acute Lymphoblastic Leukemia CTG-2406 - Standard of Care
Chronic Lymphocytic Leukemia CTG-3945 - Standard of Care
Mantle Cell Leukemia CTG-4085 - Standard of Care

Comet Assay

Comet Assay_April 2023 For Landing page

Figure 3: CTG-3950 shows extensive DNA damage after treatment with Cisplatin.

Colony Forming Unit Assay (CFU)

AML model CTG-2456 Colony forming assay

 


Figure 4
: Cytarabine inhibits cellular differentiation or proliferation in AML Model CTG-2456.